Nanobiotix is a late-stage clinical biotechnology company that develops physics-based nanotherapeutics for the treatment of cancer and neurological diseases. Founded in 2003, the company operates three nanotechnology platforms: Nanoradioenhancer, which enhances the destructive effect of radiotherapy on tumors without increasing doses to healthy tissues; Nanoprimer, designed to enable extra-hepatic administration of systemic therapies; and a platform for neurological diseases that modifies neuronal connections to alleviate symptoms. The company's lead candidate, JNJ-1900 (NBTXR3), is a first-in-class radioenhancer currently in clinical trials for solid tumors, including non-small cell lung cancer and head and neck cancers. Nanobiotix holds a global licensing agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company, for the co-development and commercialization of NBTXR3. The company maintains a subsidiary in Cambridge, Massachusetts, and serves patients globally through its clinical development programs.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage nanobiotix.com
Sector Healthcare IR page ir.nanobiotix.com
Tags
nanomedicine, radiotherapy, solid tumors, neurological diseases, oncology, clinical-stage, physics-based therapeutics, Nanoradioenhancer, Nanoprimer, JNJ-1900, NBTXR3, Curadigm Nanoprimer, Janssen Pharmaceutica NV
Press page —

Metrics

Valuation  
Market cap € 828.063M
Market cap (USD) $ 909.959M
P/E -15.85
PEG —
P/BV -9.80
P/S 99.07
P/OCF -24.22
P/FCF -24.38
Dividend yield —
Turnover / mcap —
Returns  
ROE 28.4%
ROI —
ROIC —
Profit margin -80.8%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 21
Quality score -40.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2018 FY 2017 FY 2015 FY 2013 FY 2012
Revenue 29.643M -11.609M 30.058M 4.776M 2.647M 2.512M 116K 252K — — —
Net profit -23.961M -68.132M -39.7M -57.041M -47.003M -33.59M — — — — —
Free cash flow -33.96M -20.397M -12.804M -37.196M -30.1M -27.634M — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2018 FY 2017 FY 2015 FY 2013 FY 2012
Share price 17.28 3.27 — — — — — — — — —
Price performance 12m 4.29 — — — — — — — — — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (EUR) — 62,000 0.00 101,000 905,000 2.98M 2.14M
↳ YoY growth -100.0% +796.0% +229.0% -28.2%
↳ 5y CAGR +103.0%
Cash and deposits (EUR) 35.1M 119M 83.9M 41.4M 75.3M 49.7M 52.8M
Intangible assets (EUR) — 21,000 4,000 1,000 8,000 7,000 10,000
Cash flow detail
Operating cash flow (EUR) — -27.5M -29.9M -37.1M -12.5M -19.6M -33.4M
Purchases of property, plant and equipment (EUR) — -96,000 -228,000 -92,000 -328,000 -846,000 -538,000
Purchases of intangible assets (EUR) — -11,000 -5,000 -1,000 -9,000 -2,000 -8,000
Change in receivables (cash effect) (EUR) — -51,000 62,000 -101,000 -806,000 -2.07M 840,000
Change in payables (cash effect) (EUR) — -995,000 -281,000 2.91M 8.68M 1.96M -5.41M
Interest paid (cash effect) (EUR) — -700,000 -1.13M -915,000 -6.98M -980,000 -1.53M
Income taxes paid (cash effect) (EUR) — — — 0.00 -7,000 -62,000 -198,000
Share-based compensation (EUR) — 2.92M 3.2M 3.17M 3.22M 4.3M 3.54M
Operating cash flow before change in receivables (EUR) — -27.5M -29.9M -37M -11.7M -17.5M -34.3M
Free cash flow (OCF - PPE - intangibles) (EUR) — -27.6M -30.1M -37.2M -12.8M -20.4M -34M
Income detail
Research and development expense (EUR) — 24.3M 30.4M 32.6M 38.4M 40.5M 23.1M
↳ 5y CAGR -1.0%
Total comprehensive income (EUR) — -33.5M -46.9M -57M -39.7M -68.2M -24M
Reported Apr 8, 2022 Apr 8, 2022 Apr 8, 2022 Apr 24, 2024 Apr 24, 2024 Apr 2, 2025 Mar 31, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Voting Rights and Shares Capital of the Company Bull 0 Bear 0 Routine

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

PARIS, Nov. 12, 2026 (GLOBE NEWSWIRE) --

Market: Euronext Paris / Nasdaq

Euronext Compartment: B

ISIN code: FR0011341205

Bloomberg: NANO:FP

Reuters: NANO.PA

Date

Number of Shares

Outstanding

Total number of voting rights

Total voting rights,

theoretical1 Total voting rights,

exercisable2

October 31, 2026 50,968,893 54,726,179 54,704,061

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Nanobiotix is the owner of more than 30 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

Prompts

Nanobiotix S.A. (ticker NANO), listed in France.

ETFs Holding Nanobiotix S.A.

ETF Weight in ETF Shares Market value As of
APIE 0.01% 1,649 $ 67.015K Aug 31, 2026
AVDE 0.00% 18,716 $ 534.523K Nov 16, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
NBTX Common share — US nasdaq 31.16 USD 2026-09-30
NANO canonical Common share — FR euronext 17.28 EUR 2025-11-26